Skip to main content
An official website of the United States government
Email

Artificial Intelligence (AI) Model “SCORPIO” Uses Blood Test to Predict Immunotherapy Benefits

Are you eager to use AI for tailoring immunotherapy for your patients but finding it hard to access the traditional biomarkers you need for predicting response to immune checkpoint inhibitors (ICIs)?

In a new study, funded in part by NCI, researchers tested an AI model, called SCORPIO (“Standard Clinical and labOratory featuRes for Prognostication of Immunotherapy Outcomes”) that leverages a routine blood test, along with basic clinical information.

Using such a tool, you could easily incorporate AI-immunotherapy decision-making into even the busiest clinical practice—anywhere in the world.

Senior author, Dr. Diego Chowell, of the Icahn School of Medicine at Mount Sinai, noted, “SCORPIO helps clinicians prioritize treatment by assessing the risk-benefit ratio of ICIs, especially for patients at risk of immune-related adverse events. SCORPIO also can help you in clinical trial design by selecting patients who are more (or less) likely to benefit from ICIs.”

Co-senior author, Dr. Luc G.T. Morris, of Memorial Sloan Kettering Cancer Center, added, “SCORPIO’s key advantage is its accessibility in all practice settings, including low-resource healthcare environments. Because SCORPIO uses data routinely collected in hospitals and clinics and stored in patient clinical records, it offers an approach that’s noninvasive, cost-effective, and globally accessible.”

Read the full report in Nature Medicine. For information on the code, see Zenodo.

For more information on using AI to predict immunotherapy, see the recent article on HistoTME.)

< Older Post

New Evaluation Tool Helps Researchers Discover Disease Genes and Predict Interactions

Newer Post >

Promote and Reward Data Sharing Through the NIH Data Sharing Index (S-index) Challenge

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Artificial Intelligence (AI) Model “SCORPIO” Uses Blood Test to Predict Immunotherapy Benefits was originally published by the National Cancer Institute.”

Archive

Email